Biotech is one of today’s many hot frontiers of technology, but one thing holding it back is that it’s significantly less amenable to traditional computing techniques than other areas. A new startup called Asimov, spun off from research at MIT, is working on bridging the gap between the digital and the biological by creating, essentially, a set of computer-aided biology design tools. It’s a prescient enough idea that it has attracted $4.7 million in seed funding.
The problem that Asimov addresses is this. Say you’re a pharmaceutical company trying to make a tiny biocompatible machine that holds a certain amount of medication and releases it when it senses some other molecule.
In order to do so, you’d have to — well, among about a million other things — design what amounts to a logic gate and signal processor that works at the molecular scale. This is a daunting prospect, as creating molecular machinery is a labor-intensive process often involving creating thousands of variations of a given structure and testing them repeatedly to see which works.